Goldman Sachs
BIOR

Goldman Sachs’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Goldman Sachs’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-56
Closed -$16K – 6874
2022
Q1 		$16K Buy
+56
New +$21.2K ﹤0.01% 6439
2021
Q2 		– Sell
-143
Closed -$170K – 6678
2021
Q1 		$170K Buy
143
+101
+240% +$139K ﹤0.01% 5698
2020
Q4 		$55K Buy
+42
New +$61.6K ﹤0.01% 5372
2020
Q3 		– Sell
-256
Closed -$576K – 5610
2020
Q2 		$576K Buy
+256
New +$697K ﹤0.01% 4300

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Goldman Sachs's BIOR Position: Q2 2022 in Review

Goldman Sachs sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q2 2022, closing a stake of 56 shares — an estimated $16K sold.

Goldman Sachs first reported a position in BIOR in Q2 2020 and held it in 4 quarters. The position peaked at $576K in Q2 2020. 46 funds tracked by Wall St. Rank hold BIOR as of Q2 2022.

  • Goldman Sachs reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Goldman Sachs sold 56 Biora Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $16K.
  • Goldman Sachs first reported a position in Biora Therapeutics, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
  • Goldman Sachs's Biora Therapeutics, Inc. Common Stock position peaked at $576K in Q2 2020.
  • 46 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.